HC Wainwright Estimates Skye Bioscience Q3 Earnings

Skye Bioscience, Inc. (NASDAQ:SKYE) – Investment analysts at HC Wainwright issued their Q3 2025 earnings estimates for Skye Bioscience in a research note issued to investors on Tuesday, September 30th. HC Wainwright analyst A. Ghosh forecasts that the company will earn ($0.43) per share for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Skye Bioscience’s current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Skye Bioscience’s Q4 2025 earnings at ($0.44) EPS, FY2025 earnings at ($1.61) EPS, FY2026 earnings at ($1.84) EPS, FY2027 earnings at ($1.80) EPS, FY2028 earnings at ($2.04) EPS and FY2029 earnings at ($2.47) EPS.

A number of other brokerages have also recently weighed in on SKYE. JMP Securities reiterated a “market outperform” rating and issued a $15.00 price objective on shares of Skye Bioscience in a research note on Tuesday, June 24th. Evercore ISI upgraded shares of Skye Bioscience to a “strong-buy” rating in a research report on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $14.75.

Skye Bioscience Stock Up 5.4%

NASDAQ:SKYE opened at $4.49 on Thursday. The stock’s 50 day moving average price is $3.71 and its 200 day moving average price is $2.99. The company has a market capitalization of $139.14 million, a PE ratio of -4.24 and a beta of 2.34. Skye Bioscience has a 52-week low of $1.14 and a 52-week high of $5.96.

Skye Bioscience (NASDAQ:SKYE) last posted its earnings results on Thursday, August 7th. The company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.10).

Insider Activity at Skye Bioscience

In other Skye Bioscience news, major shareholder 5Am Partners Vii, Llc sold 170,449 shares of the company’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $3.42, for a total transaction of $582,935.58. Following the completion of the transaction, the insider owned 57,493 shares in the company, valued at approximately $196,626.06. This represents a 74.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Andrew J. Schwab sold 170,449 shares of the firm’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $3.42, for a total transaction of $582,935.58. Following the completion of the sale, the director owned 57,493 shares of the company’s stock, valued at $196,626.06. This trade represents a 74.78% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 462,810 shares of company stock valued at $1,601,097 in the last 90 days. Company insiders own 4.50% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC grew its holdings in Skye Bioscience by 121.3% during the second quarter. Tower Research Capital LLC TRC now owns 10,927 shares of the company’s stock worth $46,000 after acquiring an additional 5,989 shares during the period. Qube Research & Technologies Ltd purchased a new stake in shares of Skye Bioscience during the 2nd quarter worth $218,000. Capital Advisors Wealth Management LLC grew its stake in shares of Skye Bioscience by 143.1% during the 2nd quarter. Capital Advisors Wealth Management LLC now owns 50,800 shares of the company’s stock worth $212,000 after purchasing an additional 29,900 shares during the period. Marshall Wace LLP purchased a new position in shares of Skye Bioscience in the 2nd quarter valued at about $436,000. Finally, Millington Financial Advisors LLC purchased a new position in shares of Skye Bioscience in the 2nd quarter valued at about $44,000. 21.09% of the stock is owned by hedge funds and other institutional investors.

Skye Bioscience Company Profile

Skye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.